# Verdict: hereditary_diffuse_gastric_cancer.md (re-verification after revision)

1. DOSE LEAK: none. Grepped for mg/mg-m2/AUC/dose/cycle/q-week patterns — zero hits. All numerals
   are ages/percentages/intervals (37, 30-50%, 18-40, 6-12 months, <50, <70), each matched to a
   DeVita line below. No drug dose, radiation dose, or numbered chemo schedule anywhere.

2. UNGROUNDED / MISLABELLED CLAIMS: none remaining.
   - Age of onset 37, CDH1/E-cadherin, 30-50% mutation rate, prophylactic gastrectomy age 18-40,
     6-12 month endoscopy/random-biopsy interval, and the 5-criteria genetic-counselling checklist —
     verbatim-matched to DeVita lines 101217-101227/101263-101264. Not fabricated, not mislabelled.
   - CTNNA1 minority contributor + CDH1-negative multigene panel testing — flagged inline as
     "(general oncology standard, not from DeVita's section on this disease)"; confirmed CTNNA1 does
     not appear anywhere in devita.txt. Correct.
   - Breast MRI + clinical exam + risk-reducing mastectomy option for female CDH1 carriers — this was
     the R1 gap (previously unflagged). Now relabelled "(NCCN CDH1-carrier standard, not from
     DeVita's section on this disease)". Confirmed present verbatim in the current file (line 44).
     Fixed.
   - Postoperative nutritional supplementation (B12/iron/calcium/fat-soluble vitamins) — the second
     R1 gap. Now relabelled "(general post-gastrectomy standard, not HDGC-specific in DeVita)".
     Confirmed present verbatim (line 55). Fixed.
   - "When a diffuse gastric cancer is already present" section (resection, perioperative/adjuvant
     chemo, platinum-based doublet +/- targeted/immune agents for metastatic disease) — flagged
     inline as "(general oncology standard, not from DeVita's section on this disease)", with an
     explicit statement that DeVita is silent on HDGC-specific systemic therapy. No numeric regimen
     given. Correct.
   No claim is mis-attributed to DeVita; every claim not directly traceable to the DeVita HDGC
   passage now carries an inline non-DeVita flag.

3. CITATION: present — "DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology,
   12th ed." plus NCCN Guidelines line. Name only, no page numbers. Compliant.

4. VERDICT: CLEAN (ready for R1 re-review). Both previously-flagged labelling gaps are fixed exactly
   as specified, with no other content changed (confirmed: rest of file is identical to the prior
   REVISE draft). No new dose leaks or ungrounded claims introduced.
